Introduction {#sec1}
============

Arteriosclerosis obliterans of the lower limbs is caused by the formation of atherosclerotic plaques of the lower limbs, which leads to arterial stenosis and occlusion, leading to chronic limb ischemia. Percutaneous superficial femoral interventions are the preferred treatment for superficial femoral artery disease, even though the occurrence of in-stent restenosis (ISR) continues to be an important complication \[[@B1],[@B2]\]. The mechanism of stent restenosis is unclear. Neointimal proliferation underlies the pathophysiological development of ISR and is triggered by the pro-inflammatory molecules released due to endothelial damage, particularly during the thrombogenic and proliferative phases of ISR \[[@B3]\].

Recent studies have shown that inflammatory processes play an important role not only in the occurrence and development of atherosclerosis, but also in the occurrence of ISR \[[@B4],[@B5]\]. The neutrophil--lymphocyte ratio (NLR) has been shown to be a marker of inflammation and closely related to increased cardiovascular mortality and morbidity \[[@B6],[@B7]\]. Although the relationship between various inflammatory biomarkers, including NLR, and the occurrence of ISR has been investigated \[[@B8]\]. No studies have evaluated the effectiveness of the NLR value after (NLR~after~), NLR change(NLR~change~), defined as the NLR value before (NLR~before~) and after (NLR~after~) superficial femoral artery stenting (SFAS) intervention and NLR change ratio (NLR~ratio~), defined as the ratio of NLR~change~ to NLR~before~, in prediction of ISR in superficial femoral artery stents, which are at high risk for the occurrence of ISR. The present study aims to investigating the relationship between an increase in the pre- and post-operative NLR and superficial femoral artery ISR rate.

Patients and methods {#sec2}
====================

Patient selection and research design {#sec2-1}
-------------------------------------

We recruited 199 patients that underwent SFAS for lower extremity arteriosclerosis obliterans at our hospital from March 2015 to July 2018. Inclusion criteria included the following: 1. Adult patients that underwent successful percutaneous transluminal stent implantation for superficial femoral artery lesions; 2. TASC-II classification of the femoral artery \[[@B1]\]: TASC-IIA, TASC-IIB, and TASC-IIC patients; 3. At least one arterial run-off below the knee, although stenosis lesions that were not limiting the flow may be included; 4. No evidence of residual inflow problems in the aortoiliac artery, although stenosis lesions that were not limiting the flow may be included. Exclusion criteria included the following: 1. Evidence of contraindications to anti-coagulation; 2. Active infection, chronic inflammatory disease, malignancy and chronic obstructive pulmonary disease; 3. evidence of hematological disease; 4. Presence of severe cardiac insufficiency (New York Heart Association grade III or IV), liver dysfunction (Child grade B or C) or renal insufficiency (creatinine clearance \< 30 ml/min); and 5. No arterial run-off below the knee. All patients donated venous blood 3 days before and then after implantation. Routine hematological parameters including monocyte count, eosinophil count, basophil count, platelet count, platelet distribution width, neutrophil count, lymphocyte count, and levels of triglycerides, cholesterol, high-density lipoprotein, low-density lipoprotein, Bilirubin, Albumin, were measured by an auto-analyzer (Model XE2100; Sysmex Co, Kobe, Japan). Clinical and demographic data, and laboratory results were obtained from the hospital electronic medical records system for admitted patients. Hypertension was defined as blood pressure ≥140/90 mm/Hg or treatment with anti-hypertensive medications. Diabetes mellitus was defined as fasting glucose ≥126 mg/dl or treatment with oral anti-diabetic drugs or insulin. Smokers were defined as current cigarette users or patients who had quit smoking within 1 month of the procedure.

Before the procedure, patients received dual anti-platelet therapy consisting of aspirin (100 mg/d) plus clopidogrel (75 mg/d). The contralateral cross-over approach was used for all procedures. Interventional operations were performed through a 5F or 6F sheath (length 11--45 cm). Selective angiography was performed to localize lesions and measure the range of lesions by using 4F or 5F catheter. Balloon angioplasty was performed using the predilatation technique, and the diameter of balloon was determined by angiography. Self-expanding stents were implanted with a residual diameter stenosis \>30% and/or flow-limiting dissection after balloon angioplasty in accordance with American College of Cardiology/American Heart Association guidelines \[[@B11]\]. Self-expanding stents had a diameter of 6 mm, and 5-mm diameter balloons were used for postdilatation within the stent. Percutaneous transluminal angioplasty success was defined as dilation of all arterial lesions with a residual stenosis of 20%. Stent technical success was defined as a residual stenosis of \< 20% after stent placement. All interventional procedures were performed under local anesthesia. All patients received 5000 units of heparin during the procedures. After taking 100 mg of aspirin and clopidogrel at 75 mg for 12 months, clopidogrel was discontinued and administration of aspirin was sustained. Doppler ultrasonography, computed tomography angiography or digital subtraction angiography was performed every 3--6 months after stenting the superficial femoral artery. ISR was defined as not less than 50 percent stenosis in the treated lesion \[[@B12]\]. The study was approved by the local Ethics Committee of the Fourth Affiliated Hospital of China Medical University. All patients signed an informed consent.

Statistical analysis {#sec2-2}
--------------------

Data were analyzed using the SPSS version 21.0 software package. Continuous data were given as mean ± S.D. Discrete parameters were presented as percentages. The Kolmogorov--Smirnov test was used to evaluate a normal distribution. An independent-samples *t*-test was used to compare continuous variables between the two groups. The Χ^2^ test was used to compare categorical data. Entered factors included those with *P*\<0.1 in univariate analysis. Logistic regression analysis was used to identify predictors of ISR. Receiver operating characteristic (ROC) curve analysis was used to determine the cutoff values of the NLR. A probability (*P*) value of \<0.05 was considered statistically significant.

Results {#sec3}
=======

We enrolled 199 patients to the present study, all of whom were followed up for more than 1 year, of whom 80 (40%) were determined as having ISR. There were 155 (77.9%) men and 44 (22.1%) women in this group. Patients were divided into two groups according to the occurrence of ISR within 1 year (group 1, ISR; group 2, Non-ISR). There was no difference between groups for age and sex distribution. There were 108 (54.3%) smoking, 50 (25.1%) coronary heart disease, and 112 (56.3%) hypertension patients although none were statistically different when comparing the ISR and no-restenosis groups (*P*\>0.05). In addition, the TASC II classification of the femoral artery was not statistically different between the ISR and no-restenosis groups (*P*\>0.05). Χ^2^ test analysis the diabetes mellitus statistically different between both groups (*P*=0.028). The post-interventional monocyte count was significantly different (ISR = 0.76 ± 0.28 vs Non-ISR = 0.68 ± 0.26, *P*=0.031). Although the before NLR was not different between the groups (ISR = 2.87 ± 1.12 vs Non-ISR = 3.36 ± 1.99, *P*=0.051), the NLR~after~ was significantly different (ISR = 4.94 ± 1.35 vs Non-ISR = 3.65 ± 1.55, *P*\<0.001) and the NLR~ratio~ was significantly higher in Non-ISR (ISR = 4.94 ± 1.35 vs Non-ISR = 3.65 ± 1.55, *P*\<0.001) ([Table 1](#T1){ref-type="table"}).

###### Clinical and hematological characteristics of the according to development of in-stent restenosis

                                         ISR, *n*=80 (%)   Non-ISR, *n*=119 (%)   *t*            *P* value
  -------------------------------------- ----------------- ---------------------- -------------- -----------
  Male                                   59 (73.7%)        96 (80.7%)             Χ^2^ = 1.33    0.270
  Age, Y                                 68.72 ± 11.37     70.59 ± 9.52           −1.256         0.211
  Smoking                                41 (51.2%)        67 (56.3%)             Χ^2^ = 0.492   0.562
  Hypertension                           42 (52.5%)        70 (58.8%)             Χ^2^ = 0.770   0.386
  Diabetes mellitus                      54 (67.5%)        61 (51.3%)             Χ^2^ = 5.170   0.028
  CAD                                    22 (27.5%)        28 (23.5%)             Χ^2^ = 0.400   0.620
  TASC II classification                                                                         
  TASC A                                 3                 4                      0.980          
  TASC B                                 40                59                                    
  TASC C                                 37                56                                    
  **Hematologic parameters**                                                                     
  Total cholesterol, mmol/l              4.40 ± 1.28       4.23 ± 1.19            0.929          0.354
  Triglyceride, μmmol/l                  1.76 ± 1.37       1.88 ± 1.78            −0.520         0.604
  HDL, mmol/l                            1.04 ± 0.30       1.04 ± 0.31            0.043          0.966
  LDL, mmol/l                            2.65 ± 0.95       2.39 ± 0.95            1.926          0.055
  Bilirubin, μmol/l                      12.1 ± 0.32       11.9 ± 0.13            0.930          0.422
  Albumin, g/l                           34.0 ± 1.31       33.5± 2.12             0.870          0.541
  **Hematologic parameters**                                                                     
  Pre-interventional monocyte count      0.51 ± 0.17       0.55 ± 0.31            −1.101         0.272
  Post-interventional monocyte count     0.76 ± 0.28       0.68 ± 0.26            2.179          0.031
  Pre-interventional eosinophil count    0.18 ± 0.19       0.18 ± 0.15            0.288          0.774
  Post-interventional eosinophil count   0.20 ± 0.17       0.21 ± 0.25            −0.033         0.974
  Pre-interventional basophils count     0.04 ± 0.02       0.03 ± 0.02            1.173          0.242
  Post-interventional basophils count    0.03 ± 0.01       0.04 ± 0.05            −0.842         0.401
  Pre-interventional leukocyte count     7.95 ± 1.88       8.34 ± 3.11            −0.996         0.320
  Post-interventional leukocyte count    8.62 ± 2.66       8.17 ± 2.86            1.114          0.267
  Pre-interventional platelet count      229.62 ± 77.83    232.02 ± 91.70         −0.192         0.848
  Post-interventional platelet count     210.50 ± 69.40    215.75 ± 85.39         −0.458         0.647
  Post-interventional PDW,%              16.91 ± 0.88      16.61 ± 1.18           1.899          0.059
  Post-interventional PDW,%              18.24 ± 0.65      17.47 ± 3.61           1.868          0.063
  Pre-interventional neutrophil count    5.32 ± 1.61       5.23 ± 1.65            0.366          0.715
  Post-interventional neutrophil count   9.22 ± 1.07       5.80 ± 2.04            13.719         \<0.001
  Pre-interventional lymphocyte count    2.00 ± 0.64       1.82 ± 0.66            1.888          0.061
  Post-interventional lymphocyte count   1.95 ± 0.41       1.70 ± 0.52            3.643          \<0.001
  NLR~before~                            2.87 ± 1.12       3.36 ± 1.99            −1.963         0.051
  NLR~after~                             4.94 ± 1.35       3.65 ± 1.55            6.071          \<0.001
  NLR~change~                            2.07 ± 1.48       0.29 ± 1.86            7.136          \<0.001
  NLR~ratio~                             0.93 ± 0.80       0.31 ± 0.63            6.099          \<0.001

Abbreviations: CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NLR, neutrophil--lymphocyte ratio.

The predictors of ISR in the multivariate logistic regression analyses are presented in ([Table 2](#T2){ref-type="table"}). Because NLR~after~, NLR change(NLR~change)~ and NLR~ratio~ were inflammatory markers, they were not considered together in the multivariate model. Therefore, three multivariate models including NLR~after~ (NLR~after~, model 1), NLR~change~ (NLR~change~, model 2) and NLR~ratio~ (NLR~ratio~, model 3) were separately constructed. A NLR~after~ \> 4.3 was associated with an odds ratio of 1.946 (95% CI \[1.51--2.50\]; *P*\<0.001) for the presence of ISR. A NLR~change~ \> 1.24 was associated with an odds ratio of 2.17 (95% CI \[1.63--2.88\]; *P*\<0.001) for the presence of ISR; A NLR~ratio~ value \>37.5% was associated with an odds ratio of 3.6 (95% CI \[2.03--6.36\]; *P*\<0.001) for the occurrence of ISR. Among these, NLR~ratio~ was found to be significant independent predictor of ISR in the multivariate logistic regression analysis. Pearson's correlation analysis showed that NLR~ratio~ was positively correlated with the onset time of ISR (*r* = 0.41; *P*\<0.001).

###### Multivariate analysis of predictors of ISR after superficial femoral artery stenting

  Variables                             Model 1 (NLR~after~)   Model 2 (NLR~change~)   Model 3 (NLR~ratio~)                                 
  ------------------------------------- ---------------------- ----------------------- ---------------------- --------- ------------------- -------
  Post-interventional monocyte count    1.294 (0.38--4.35)     0.677                   1.81 (0.52--6.33)      0.350     2.18 (0.67--7.05)   0.192
  Pre-interventional lymphocyte count   2.272 (1.33--3.86)     0.003                   0.80 (0.46--1.38)      0.437     0.78 (0.44--1.36)   0.389
  LDL                                   1.275 (0.89--1.75)     0.182                   1.43 (1.02--2.01)      0.037     1.36 (0.98--1.89)   0.059
  Pre-interventional PDW                1.116 (0.79--1.55)     0.522                   1.16 (0.82--1.66)      0.384     1.18 (0.84--1.64)   0.326
  Post-interventional PDW               1.07(0.95--1.21)       0.251                   1.05 (0.92--1.20)      0.453     1.05 (0.91--1.21)   0.463
  Diabetes mellitus                     0.59(0.30-1.19)        0.144                   0.73 (0.36--1.47)      0.383     0.72 (0.37--1.42)   0.354
  NLR~change~                           ---                    2.17 (1.63--2.88)       \<0.001                ---                           
  NLR~ratio~                            ---                    ---                     3.6 (2.03--6.36)       \<0.001                       
  NLR~after~                            1.946 (1.51--2.50)     \<0.001                 ---                    ---                           

Abbreviations: LDL, low-density lipoprotein; NLR, neutrophil--lymphocyte ratio; PDW, platelet distribution width.

A NLR~after~ level \> 4.3 predicted ISR with 75% sensitivity and 76% specificity for the prediction of ISR, as identified by the ROC curve. The area under the ROC curve (AUC) was 0.779 (95% CI \[0.71--0.84\], *P*\<0.001). A NLR~change~ level \> 1.24 predicted ISR with 75% sensitivity and 77% specificity, AUC was 0.785 (95% CI \[0.72--0.85\], *P*\<0.001). A NLR~ratio~ level \> 37.5% had 77% sensitivity and 60% specificity. AUC was 0.741 (95% CI \[0.67--0.81\], *P*\<0.001). The ROC curves of NLRafter, NLR~change~ and NLR~ratio~ were not significantly different, and the clinical diagnostic efficacy was almost the same. The ROC curve comparison of these three markers is shown in [Figure 1](#F1){ref-type="fig"}.

![The ROC curves of NLR~after~, NLR~change~ and NLR~ratio~ were not significantly different, and the clinical diagnostic efficacy was almost the same\
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Discussion {#sec4}
==========

Atherosclerosis is a progressive, complex and multifactorial disease. Inflammation plays an important role in all stages of the atherosclerosis development \[[@B13],[@B14]\]. ISR has been attributed to neointimal hyperplasia in the early stage after the procedure \[[@B15]\]. Inflammatory cells may accelerate neointimal hyperplasia because of their release of growth and chemotactic factors \[[@B16]\] or production of enzymes (e.g. matrix metalloproteinases), which can degrade extracellular constituents and facilitate cell migration \[[@B17],[@B18]\]. Neutrophils respond to different inflammatory stimuli resulting in release of various cytokines and cytotoxic/proteolytic enzymes that affect the vascular system by numerous mechanisms such as induction of damage to endothelial cells, induction of the coagulation system \[[@B19]\]. Lymphocyte count reflects a physiologic stress response to cortisol \[[@B20]\]. The NLR has been shown to be a marker of inflammation and closely related to increased cardiovascular mortality and morbidity \[[@B5],[@B6]\]. The primary finding of our study is that the NLR~ratio~ level was a better independent predictor than NLR~after~ level for the occurrence of the ISR in patients who underwent superficial femoral artery stenting for lower extremity arteriosclerosis obliterans.

Our study observed that in patients presenting with restenosis within 12 months, the NLR increased after stent implantation. We find a positive correlation between the NLR~ratio~ and an occurrence of ISR (*r*=0.41; *P*\<0.001). Patients with a NLR~ratio~ value \> 37.5% had a 3.47-fold higher risk of ISR when compared with a NLR~ratio~ value \< 37.5%. Patients with a NLR~after~ value \> 4.3 had a 1.96-fold higher risk of ISR when compared with a NLR~after~ value \< 4.3. Moreover, patients with a NLR~change~ \> 1.24 had a 2.13-fold higher risk of ISR than did patients with a NLR~change~ value \< 1.24. A NLR~ratio~ level \> 37.5% had 77% sensitivity and 60% specificity for the prediction of ISR, A NLR~change~ level \> 1.24 predicted ISR with 75% sensitivity and 77% specificity. The NLR~change~ in our study is higher than that reported in most other studies. For example, Balli et al. \[[@B21]\] reported the neutrophil--lymphocyte ratio for prediction of in-stent restenosis in coronary stents. A NLR~change~ level \> 0.58 had 81.8% sensitivity and 93.5% specificity for the prediction of ISR. This discrepancy might be caused by the different lesion sites studied. The superficial femoral artery stent might be affected by the compression, pulling and torsion of the thigh muscle, resulting in continuous vascular damage, while the coronary arteries are less affected by the muscle. Chang et al. \[[@B10]\] reported that the NLR~before~ \> 3.62 was independently and positively associated with a higher risk of early (within 1 year) ISR after stent implantation in patients with femoropopliteal chronic total occlusion. His results differ from ours in that we did not find a relationship between the NLR~before~ levels and the occurrence of ISR. The differences may be: first, we excluded patients with active infection, chronic inflammation, malignancy, and copd. Inflammation is considered to play a key role in the pathophysiological process for many chronic diseases. Second, they mainly studied the chronic complete occlusion of femoral popliteal artery, while we mainly studied the superficial femoral artery, and the patients did not have severe limb ischemia. In addition, the relationship between post-operative NLR and stent restenosis has not been analyzed.

Occurrence of ISR is a complex and multifactorial process \[[@B22]\]. Inflammation appears to be one of the many risk factors for stent restenosis \[[@B22],[@B23]\]. The inflammatory process plays an important role not only in initiation and progression of atherosclerosis \[[@B14]\] but also in development of stent restenosis \[[@B24],[@B25]\]. In general, the inflammation process contributes to stent restenosis by two distinct mechanisms, namely local vascular inflammation because of mechanical injury inflicted by stent implantation \[[@B24]\] and a pre-existing systemic inflammatory state before the procedure. \[[@B22],[@B23]\]. The association between systemic inflammation and ISR has been reported in various studies conducted on different inflammatory markers. Of those, CRP was the most frequently studied biomarker owing to its accurately reflecting systemic inflammation \[[@B26]\] and being a strong predictor of cardiovascular outcomes \[[@B27]\]. Our research is mainly discussed because of mechanical damage caused by stent implants, namely, local vascular inflammation. Donners reported that \[[@B3]\] depending on endothelial damage during the PCI, increases in adhesive molecules and chemotactic factors are followed by the accumulation of inflammatory cells and pro-inflammatory molecules, such as interleukin-1 and 6, which mediate the development of neointimal proliferation. In our study, NLR~ratio~ was stronger independent predictors of short-term survival than other leukocytes. The predictive superiority of NLR may be due to 1 factor, NLR is a ratio of two different yet complementary immune pathways. Neutrophils are responsible for active ongoing nonspecific inflammation through secretion of many inflammatory mediators, like elastase \[[@B28]\], myeloperoxidase \[[@B28]\] and oxygen free radicals that can facilitate plaque disruption. An increase in neutrophil count predicts an increase in neointima and undesirable outcomes of stent restenosis. Lymphocytes, in contrast, represent the regulatory pathway of the immune system. CD4, the main subtype of total lymphocyte count, reflects a physiologic stress response to cortisol \[[@B20]\].The neutrophil--lymphocyte ratio therefore reflects both the neutrophil of inflammation and the relative lymphocyte of cortisol-induced stress response. In consequence, high NLR reflects two different immune pathways; hence, it is more predictive than either parameter alone.

In addition, we found that the proportion of diabetic patients in ISR group was significantly higher than that in non-ISR group, and the difference between ISR group and non-ISR group was significant. Diabetes mellitus has been shown to be an important risk factor for poor prognosis in patients with cardiovascular interventional therapy \[[@B30]\]. This is consistent with our observation that diabetes is an important factor for poor prognosis after superficial femoral artery stent implantation, but our findings suggest that diabetes is not an independent risk factor for ISR.

Our study has several limitations. This study was conducted on a retrospective basis and represented a single center experience. Second, the limitations of our study were the small sample, which we recognize might lead to differences in some of the reported observations.

In conclusion, NLR~ratio~ could be used as an inexpensive and easy-to-access method for assessment of inflammatory status and prognosis in patients with superficial femoral artery stents.

Highlights {#sec5}
==========

1.  Determine the risk factors of restenosis in superficial femoral artery stents early in clinical treatment by simple and convenient examination methods.

2.  Evaluate the studies that investigating NLR~ratio~ and to identify the prognostic and diagnostic value of NLR~ratio~ as an inexpensive and easy-to-access parameter after superficial femoral artery stents.

3.  The new findings of this work have deepened the current understanding of in-stent restenosis in the superficial femoral artery and provide a theoretical basis for the prevention of ISR. As such the findings are valuable for future studies.
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